REGN FY 2015 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2015 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4.1B+45.5% YoY

Gross Profit

$3.6B88.6% margin

Operating Income

$1.3B30.5% margin

Net Income

$636M15.5% margin

EPS (Diluted)

$5.52

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$653M

Stock-Based Comp.

$459M

Balance Sheet

Total Assets

$5.6B

Total Liabilities

$2.0B

Stockholders' Equity

$3.7B

Cash & Equivalents

$809M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.1B	$2.8B	+45.5%
Gross Profit	$3.6B	$2.6B	+41.9%
Operating Income	$1.3B	$824M	+51.9%
Net Income	$636M	$348M	+82.7%